May 24, 2023 – ATG-022 Receives FDA Orphan Drug Designation for Gastric/Pancreatic Cancers

The FDA has granted orphan drug designation to ATG-022, a Claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC), for the treatment of patients with gastric cancer and pancreatic cancer, according to a press release from developer Antengene Corporation Limited.¹

Read More>

Posted in Articles

← May 19, 2023 – GEN-001/Avelumab Combination Induces Antitumor Activity in Gastric and GEJ CancerMay 24, 2023 – Claudin-18.2 Emerges as a Novel Therapeutic Target in GI Malignancies →